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Abstract 52 
IMPORTANCE 53 
Clinical features are unreliable for distinguishing Ocular Surface Squamous Neoplasia 54 
(OSSN) from benign conjunctival lesions.   55 
 56 
OBJECTIVE 57 
To evaluate the adverse effects, accuracy and inter-observer variation of Toluidine Blue 58 
0.05% vital staining in distinguishing OSSN, confirmed by histopathology, from other 59 
conjunctival lesions.   60 
 61 
DESIGN, SETTING AND PARTICIPANTS 62 
Cross-sectional study in Kenya from July 2012 through July 2014 of 418 adults with 63 
suspicious conjunctival lesions. Pregnant and breastfeeding women were excluded.  64 
 65 
EXPOSURES 66 
Comprehensive ophthalmic slit-lamp examination was conducted. Vital staining with 67 
Toluidine Blue 0.05% aqueous solution was performed before surgery. Initial safety testing 68 
was conducted on large tumours scheduled for exenteration looking for corneal toxicity on 69 
histology before testing smaller tumours. We asked about pain or discomfort after staining 70 
and evaluated the cornea at the slit lamp for epithelial defects. Lesions were photographed 71 
before and after staining. Diagnosis was confirmed by histopathology. Six examiners 72 
assessed photographs from a sub-set of 100 consecutive participants for staining and made 73 
a diagnosis of OSSN vs Non-OSSN.  74 
 75 
MAIN OUTCOMES AND MEASURES 76 
Staining was compared with histopathology to estimate sensitivity, specificity and predictive 77 
values. Adverse effects were enumerated. Inter-observer agreement was estimated using 78 
the kappa statistic (k). 79 
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 80 
RESULTS 81 
143/419 (34%) participants had OSSN by histopathology. The median (interquartile range) 82 
age of the 419 was 37 (32-45) years and 278 (66%) were female. 322/419 participants had 83 
positive staining while 2/419 were equivocal. There was no histological evidence of corneal 84 
toxicity. Mild discomfort was reported by 88 (21%) and mild superficial punctate keratopathy 85 
seen in 7 (1.7%).For detecting OSSN, Toluidine blue had a sensitivity of 92% (95%CI, 87%-86 
96%), specificity 31% (95%CI, 25%-36%), positive predictive value 41% (95%CI, 35%-46%), 87 
and negative predictive value 88% (95%CI, 80%-94%). Inter-observer agreement was 88 
substantial for staining (k=0.8) and moderate for diagnosis (k=0.4).    89 
 90 
CONCLUSION AND RELEVANCE 91 
With the high sensitivity and low specificity for OSSN compared with histopathology among 92 
patients with conjunctival lesions, Toluidine Blue 0.05% vital staining is a good screening 93 
tool, but not a good diagnostic tool due to a high frequency of false positives. The high 94 
negative predictive value suggests that a negative staining result indicates that OSSN is 95 
relatively unlikely.  96 
 97 
 98 
 99 
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Background 100 
Ocular surface squamous neoplasia (OSSN) is an aggressive eye cancer, particularly 101 
affecting young adults in Africa, causing visual disability, high morbidity and mortality. The 102 
diagnosis is problematic. In most African countries pathology services are limited; most 103 
clinicians depend on their clinical judgment.1, 2 However, the appearance of OSSN overlaps 104 
with several benign conditions making a clinical impression unreliable. Surgical excision is 105 
the mainstay of OSSN treatment. A simple diagnostic test would help clinicians plan 106 
management, for example, by better delineating the boundaries of the lesion during excision. 107 
The test may also help in distinguishing early recurrent tumour from non-malignant abnormal 108 
tissue such as fibrosis, possibly avoiding the need for additional surgery.  109 
 110 
Vital stains are used to colour living tissues. Several dyes are used extensively in ophthalmic 111 
surgery.3, 4 Toluidine blue (ToB) is an acidophilic metachromatic dye that stains abnormal 112 
tissue dark royal blue by penetrating into the nuclei of cancerous cells where it has a 113 
selective affinity for nucleic acids and by accumulating in the intercellular spaces.5 Malignant 114 
tissues stain more frequently than healthy epithelia because of their abundant nuclear 115 
material from increased mitoses and poor cell-to-cell adhesion.6, 7 Mucin and inflammatory 116 
cells also take up ToB.5, 7 ToB has been used safely for many years to aid the clinical 117 
diagnosis of oral and oropharyngeal cancer and to demarcate tumours during surgical 118 
excision.8, 9  119 
 120 
A case report from Japan described the first use of topical ToB 0.05% vital staining for 121 
OSSN.10 The dye was reported to clearly demarcate the abnormal tissue, assisting the 122 
excision. The authors commented that ToB did not stain other conjunctival lesions such as 123 
pterygium (no data presented) and it was not toxic to the ocular surface. Two relatively small 124 
studies recently evaluated vital staining for OSSN using ToB 1% in Brazil and methylene 125 
blue 1% in South Africa.11, 12  However, given the variation in clinical phenotype and 126 
prevalence of conjunctival lesions it is necessary to test this in the local setting. 127 
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 128 
The aim of this study was to investigate the utility of Toluidine Blue 0.05% solution in 129 
detecting neoplastic tissue by evaluating its safety, accuracy and inter-observer variation.  130 
 131 
 132 
Methods 133 
Ethical Approval 134 
This study was formally reviewed and approved by the Kenyatta National Hospital – 135 
University of Nairobi Ethics and Research Committee (KNH-UON ERC) and the London 136 
School of Hygiene and Tropical Medicine Ethics Committee. This study adhered to the 137 
tenets of the Declaration of Helsinki. All participants gave informed written consent to take 138 
part in the study before enrolment and did not receive a stipend to participate. 139 
 140 
Participants 141 
The study was conducted between July 2012 and July 2014 in four eye care centres in 142 
different parts of Kenya; Kenyatta National Hospital in Nairobi the capital city, PCEA Kikuyu 143 
Eye Unit in Central Kenya, Kitale District Hospital in the north Rift Valley and Sabatia Eye 144 
Hospital in western Kenya bordering Lake Victoria. It was part of a larger project on the 145 
epidemiology and management of OSSN in Kenya. These centres receive referral cases 146 
from the surrounding hospitals. 147 
 148 
Consecutive adult patients (at least 18 years of age) seen in these four eye clinics with 149 
conjunctival lesions (first presentation or recurrence) suspected to be OSSN scheduled for 150 
surgery who gave consent to participate in the study were included. Pregnant women and 151 
breastfeeding mothers were excluded. 152 
 153 
Toluidine Blue Eye Drops 154 
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Toluidine Blue 0.05% aqueous solution was prepared in the Kikuyu Eye Unit eye drop 155 
production facility. Toluidine powder (Sigma Aldrich, UK) 0.05g was diluted in 100ml of 156 
freshly distilled water and aliquoted into 5ml eye drop bottles. The bottles were sterilised in a 157 
water bath at 98oC for 30 minutes and checked for particles. Any with particles was 158 
discarded. A bottle was used for up to 28 days once opened. New batches were prepared 159 
every 6 months. 160 
 161 
Clinical Assessment 162 
A comprehensive ophthalmic examination was conducted using a slit lamp. Clinical features 163 
of lesions were assessed including inflammation, leukoplakia and involvement of adjacent 164 
structures Vital staining with Toluidine Blue 0.05% solution was performed at the slit lamp 165 
before surgery. One drop of the dye was applied to the ocular surface waiting for 30 seconds 166 
before wiping off the excess spillover from the eyelids with a soft tissue paper. Topical 167 
anaesthetic was not applied before staining in order to evaluate if ToB was painful. Staining 168 
with fluorescein was not done to avoid interference with the ToB dye. 169 
 170 
Surgery and Histopathology 171 
All lesions were excised under infiltration local anaesthetic using an operating microscope 172 
with a 3mm clear margin. The defect was reconstructed by primary closure. Cryotherapy 173 
was not applied as the participants with OSSN were invited to enroll in an additional 174 
treatment trial post-operatively. Specimens were placed directly into buffered formalin and 175 
subsequently examined at the histopathology laboratory at the MP Shah Hospital, Nairobi. 176 
One pathologist examined all the histology slides. Participants with mild, moderate or severe 177 
conjunctival intraepithelial neoplasia (CIN I, II, III), carcinoma-in-situ (CIS) or invasive 178 
squamous cell carcinoma (well, moderately and poorly differentiated) were classified as 179 
having OSSN. The diagnosis of actinic keratosis was based on the presence of elastotic 180 
stromal degeneration, acanthosis, hyperkeratosis and parakeratosis in the presence of 181 
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normal cellular polarity. By the accepted criteria for dysplasia, such lesions were classified 182 
as CIN only if there was loss of polarity. 183 
 184 
a) Safety study 185 
There is extensive experience on the safety of using ToB in the oral cavity but only relatively 186 
limited data on the eye.9, 11-14 Therefore, we conducted initial testing on large tumours 187 
scheduled for exenteration. The exenteration specimens were examined by a 188 
histopathologist for evidence of corneal toxicity such as necrosis or inflammatory cells and 189 
dye penetration into the stroma (free or engulfed in macrophages).  190 
 191 
The results of the safety data and information from previous published series were reported 192 
to the ethics committee and permission was granted to extend testing to participants with 193 
smaller lesions. Participants were asked about pain or discomfort, and we evaluated the 194 
cornea at the slit lamp for epithelial changes such as punctate staining. 195 
 196 
b) Accuracy study 197 
Staining was recorded using a 5-point system as: none, equivocal (if it was too pale to be 198 
sure there was staining), pale blue, mixed pattern (pale and deep blue) or deep royal blue 199 
(Figure 1). For the purpose of analysis, any blue staining was considered positive and 200 
equivocal staining excluded from the analysis. A stratified analysis by degree of staining was 201 
also conducted. Since it would be unlikely that a clinician would be in doubt about the likely 202 
diagnosis in patients with large orbital tumours, orbital cases were excluded from this 203 
analysis. Staining (positive vs negative) was compared to histopathology (OSSN vs not 204 
OSSN).  205 
 206 
c) Inter-observer variation study 207 
The eye was photographed before and about 30 seconds after staining for subsequent 208 
independent grading of the staining pattern. A pair of photographs was taken, one in primary 209 
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gaze and the other with the lesion in the centre using a Nikon D90 digital camera with 210 
105mm lens.  211 
 212 
Six final year residents in the Department of Ophthalmology, University of Nairobi at 213 
Kenyatta National Hospital were trained by one author (SG) using projected slides showing 214 
different degrees of Toluidine blue staining. They were informed that previous studies 215 
suggested that generally OSSN stained positive and benign lesions were negative, but this 216 
may not be invariably the case. A week later the same group independently assessed 217 
photographs from the last 100 consecutive participants enrolled into the study from one 218 
centre. Cases with features that are highly suggestive of malignancy, such as very large 219 
tumours invading the orbit were excluded. The trainer (SG) projected the images on a 220 
screen. None of the slides had been shown in the training session. The residents were 221 
masked to the diagnosis and did not discuss the cases. They were asked to grade the 222 
staining and suggest a diagnosis (OSSN vs non-OSSN), taking into account the clinical 223 
features of the lesion. The clinical case-mix in this sample of patients was comparable to the 224 
whole dataset that included patients from all four study centres.   225 
 226 
Statistical Analysis 227 
Data was managed in Access (Microsoft Windows 2010) and transferred into STATA version 228 
12.1 (StataCorp, College Station, Texas, USA) for analysis. Sensitivity,  specificity and 229 
predictive values of ToB vital staining were computed based on subsequent histological 230 
diagnosis.  231 
 232 
For the inter-observer component, the scores for each clinician were compared to a 233 
reference standard using the kappa (k) statistic and graded using the Landis & Koch 234 
method.15 The examiners’ staining score was compared to the lead author’s assessment 235 
while their clinical diagnosis was compared to the histopathology report. The proportions 236 
they scored as positive or negative for stain and OSSN or non-OSSN for diagnosis were 237 
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reported. To calculate an average value, the kappa statistics for each grader were 238 
transformed to Z scores using the Fisher Z transformation, averaged, and then back-239 
transformed to a kappa statistic.     240 
 241 
Results 242 
Study Participants and Histological Diagnosis 243 
A STARD diagram is shown in eFigure 1. Five hundred and thirty-seven (537) participants 244 
with conjunctival lesions were recruited to the larger OSSN project and 447 (83%) 245 
underwent Toluidine blue staining. There were 90 people recruited into the larger study while 246 
awaiting completion of the initial ToB safety phase. The final analysis consisted of 419 247 
participants whose median (interquartile range) age was 37 (32-45) years and 277 (66%) 248 
were female. There were 143 (34%) OSSN and 276 (66%) non-OSSN lesions (Table 1).  249 
 250 
a) Safety study 251 
Seven participants with very large tumours (all were squamous cell carcinoma) were 252 
enrolled in the pilot toxicity study. None showed evidence of corneal toxicity on histology. 253 
Seven participants out of the 419 (1.7%) had a mild superficial punctate keratopathy around 254 
the lesion after vital staining possibly due to disruption of the tear film by the raised lesion 255 
and the associated drying. These were distributed as follows; 4 pterygium, 1 carcinoma in 256 
situ, 1 moderately differentiated squamous cell carcinoma and 1 capillary haemangioma. 257 
Most participants tolerated the stain well; 88/419 (21%) reported some mild discomfort 258 
immediately after application, all of which resolved rapidly.   259 
 260 
b) Accuracy study 261 
Different patterns and intensities of Toluidine Blue staining were seen (Figure 1). The seven 262 
orbital tumours in the safety phase all stained deep royal blue. Two participants out of 419 263 
showed equivocal staining and were removed from the analysis. One had moderate 264 
intraepithelial dysplasia and the other a nevus.  265 
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 266 
Overall 322 of 417 (77%) smaller lesions stained with ToB, and staining was more frequent 267 
in the OSSN group (Table 2). Any blue ToB staining had a high sensitivity (92%; 95%CI, 268 
87%-96%), low specificity (31%; 95%CI, 25%-36%), high negative predictive value (88%; 269 
95%CI, 80%-94%) and low positive predictive value (41%; 95%CI, 35%-46%) compared to 270 
histology (Table 3). The low specificity was attributable to a high proportion (69.5%) of 271 
benign lesions staining positive (65% of pterygia and 76% of actinic keratosis).  272 
 273 
Deep royal blue staining demarcated the extent of the lesion well. A mixed staining pattern 274 
was observed in which only parts of the lesion would stain particularly actinic keratosis 275 
(Figure 1F). Mucus discharge also stained blue and should ideally be wiped away before 276 
staining. Also 133/275 (48%) of benign lesions had leukoplakia which stained blue. Brown 277 
pigmentation was found in 194 (47%) lesions. These included 12 cases of conjunctival 278 
naevi. Pigmentation made interpretation of staining more difficult (Figure 1L).   279 
 280 
c) Inter-observer variation study 281 
Staining results were easy to interpret. The scores of the six graders were similar to the lead 282 
author’s (agreement 91.3%) (Table 4). The lead author found 79% of the lesions stained with 283 
ToB, compared to an average of 76.5% for the six graders. The average kappa for staining 284 
scores was substantial (k=0.76). The six graders scored more lesions as OSSN compared to 285 
histopathology (53% vs 32%). The average kappa for diagnosis was moderate (k=0.40).  286 
 287 
 288 
Discussion 289 
This is the largest study to date to evaluate ocular surface vital staining for the diagnosis of 290 
OSSN. It confirms findings from earlier studies that topical toluidine blue 0.05% is not 291 
associated with any significant adverse effects and found that the large majority of OSSN 292 
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tumours stain.11, 12 The intensity of dark blue staining seen with the 0.05% preparation was 293 
similar to 1% solutions reported in other studies in South Africa and Brazil. 294 
 295 
There were minimal side effects of vital staining. The mild superficial punctate keratopathy 296 
we observed may be attributable to dry eye due to disturbance of the tear film by the raised 297 
lesion. Dry eye is the most common ocular surface manifestation of HIV with a prevalence of 298 
up to 54%.16, 17 The mild discomfort reported on application of ToB may be aggravated by 299 
dry eye syndrome. The use of topical anaesthetic before vital staining may prevent this. 300 
Safety studies in animals found that intraocular injection (as opposed to topical use) of 1% 301 
and 2% ToB caused irreversible damage to all the corneal layers; 0.5% damaged the 302 
stromal keratocytes and corneal endothelium but 0.25% stained the lens capsule and did not 303 
damage any corneal layer or the trabecular meshwork.18 Wander et al conducted animal 304 
safety studies in rabbits and guinea pigs by applying eye drops of 0.01%, 0.1%, 0.25%, 305 
0.5%, and 1.0% toluidine blue to stain corneal epithelial cells. The cells picked up the vital 306 
dye within 5 minutes. Wash out time was rapid and no toxic effects were observed.19  307 
 308 
The diagnostic accuracy results of our study are similar to the ones from Brazil and South 309 
Africa showing high sensitivity and only low to moderate specificity (Table 3).11, 12 However, 310 
our study indicates that the sensitivity and specificity may not be quite as high as the two 311 
earlier, smaller studies had suggested. From the clinical standpoint however, the measure of 312 
accuracy that is more important than sensitivity or specificity is the predictive value. The 313 
positive predictive value in our study (41%) was lower than the South African (60%) and 314 
Brazilian (73%) studies. A caveat to such comparison is that the estimates of predictive 315 
values are only valid for the actual study population and similar populations with the same 316 
disease prevalence.  317 
 318 
The South African study had a similar patient profile to ours with regard to age, sex and HIV 319 
infection.12 However, there were some of key differences: they used Methylene blue 1% dye 320 
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and had a higher proportion of OSSN. Importantly, they combined the CIN lesions with 321 
benign lesions in their analysis, while we classified all CIN as part of the OSSN spectrum. 322 
They do not report how the CIN cases stained or whether there were different patterns of 323 
staining (pale or mixed). The patients in the Brazilian study were older than the Kenyan and 324 
South African study participants and were predominantly male (62%). Their HIV prevalence 325 
was not reported. This probably reflects different patterns of disease. The classification of 326 
OSSN and the grading systems for describing the staining in the Brazilian and Kenyan 327 
studies were similar. However, in the Brazilian study the concentration of Toluidine blue (1%) 328 
was 20 times that used in Kenya. 329 
 330 
The differences observed in the test performance between these three studies could have a 331 
number of explanations. Firstly, it may reflect the larger sample size. There could be 332 
differences in patient populations, lesions included and diagnostic methods. We found lesion 333 
pigmentation made it more difficult to be certain about staining. The other two studies do not 334 
report on pigmentation. Our study had a higher proportion and wider variety of non-OSSN 335 
lesions than the other two. In addition, the gold standard for diagnosis of OSSN, 336 
histopathology, is open to interpretation.20  337 
ToB has a higher sensitivity and specificity for oral cancers than we observed in our study. A 338 
Cochrane systematic review showed variable sensitivity of 50% to 97% and a more uniform 339 
specificity of 98% to 99%.8  However the prevalence of disease varied widely (1.4% to 340 
50.9%). The difference between ocular and oral performance of ToB is unclear. Oral rinsing 341 
with 1% acetic acid before staining removes the surface debris (glycoprotein layer) and 342 
dehydrates cells.21 This may remove keratotic surface plaques which stained deep blue in 343 
our study (Figure 1). False positives may be further explained by the fact that ToB also 344 
stains inflammatory cells and mucin.7 Also OSSN, pterygia and actinic keratosis may be on 345 
the same causal pathway due to their association with ultraviolet radiation, p53 mutation and 346 
HPV with some regarding actinic keratosis and pterygia as pre-malignant lesions.22-24 They 347 
may therefore stain similarly.  348 
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 349 
The interpretation of staining results was relatively straightforward and had higher inter-350 
observer agreement (k=0.76) than clinical diagnosis (k=0.40). Clinical diagnosis is more 351 
difficult due to the overlap in clinical features of OSSN and Non-OSSN.  352 
 353 
This study had various limitations. Firstly, the concentration, purity and stability of ToB may 354 
have changed over time once a bottle was opened. A rising concentration may have 355 
increased the staining of all lesions. Secondly, in the analysis using 2x2 contingency tables, 356 
staining is treated as a dichotomous variable while in fact there are different degrees of 357 
intensity of blue staining. There was a high frequency of lesion pigmentation in this 358 
population but the use of more concentrated ToB may be toxic given its cell nucleus entry 359 
and may increase the false positive rates by staining more benign lesions. 360 
 361 
If a test has a high sensitivity, a negative result has a high chance of ruling out the disease.25 362 
Toluidine blue had a high sensitivity so a negative result makes OSSN unlikely does not 363 
completely rule it out. 364 
 365 
In conclusion, ToB staining is safe and easily interpreted by different observers. Very few 366 
OSSN lesions did not stain with ToB. If ToB staining is negative then OSSN is unlikely. 367 
Positive staining demarcates conjunctival lesions well which could help in delineating the 368 
surgical excision margin particularly for circumlimbal OSSN lesions where both the corneal 369 
and conjunctival extents would otherwise not be clearly seen. Staining also detected small 370 
recurrences of OSSN (eFigure 2). ToB vital staining would not replace histopathology. The 371 
high sensitivity and low specificity makes ToB a good screening tool where there is an 372 
important penalty for missing a disease.  In populations with limited histopathology services, 373 
an algorithm combining ToB staining with other clinical features may raise the composite 374 
specificity for OSSN.  375 
 376 
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Figure title and legend 458 
Figure 1. Toluidine blue 0.05% staining intensities and patterns; a 5-point scale.  459 
 460 
The pictures in the left column show the lesions before staining and on the right after staining. 461 
 462 
 463 
 464 
 465 
 466 
 467 
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Table 1. Toluidine blue staining patterns of 418 conjunctival lesions  468 
Histopathology Staining result Total 
 None Pale blue Mixed Dark royal blue Equivocal
 No. (%) No. (%) No. (%) No. (%) No. (%)
OSSN 11 (7.7) 23 (16.2) 17 (11.9) 91 (64.1) 1 (0.7) 143
Pterygium 55 (34.8) 24 (15.2) 31 (19.6) 48 (30.4) 0 (0) 158
Actinic Keratosis 20 (23.8) 15 (17.9) 19 (22.6) 30 (35.7) 0 (0) 84
Nevus 4 (33.3) 1 (8.3) 4 (33.3) 2 (16.7) 1 (8.3) 12
Squamous papilloma 1 (10.0) 4(40.0) 1(10.0) 4 (40.0) 0 (0) 10
Pyogenic granuloma 2 (66.7) 0 (0) 0 (0) 1 (33.3) 0 (0) 3
Haemangioma 0 (0) 0 (0)  0 (0) 2 (100.0) 0 (0) 2
Ocular rhinosporidiosis 0 (0) 0 (0) 0 (0) 2 (100.0) 0 (0) 2
Chronic conjunctivitis 0 (0) 0 (0) 1 (50) 1 (50) 0 (0) 2
Epidermoid cyst 0 (0) 0 (0)  0 (0) 1 (100) 0 (0) 1
Sarcomatoid spindle cell tumour a 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 1
Sebaceous hyperplasia of the caruncle 1 (100.0) 0 (0) 0 (0) 0(0) 0 (0) 1
Total 95 (22.5) 67 (16.0) 73 (17.5) 182 (43.5) 2 (0.5) 419
Abbreviations: OSSN, ocular surface squamous neoplasia 469 
a this was a non-OSSN malignancy 470 
 471 
 472 
 473 
 474 
19 
 
Table 2. The association between vital staining with Toluidine Blue 0.05% and 475 
histological category (OSSN or Not OSSN). 476 
Staining result OSSN  
n(%) 
Not OSSN
n(%) 
Total
 
OR (95% CI) 
 
p-value 
Any blue staining 131 (92.3%) 191 (69.5%) 322 5.2 (2.6-10.4) <.001 
No staining 11 (7.8%) 84 (30.6%) 95 1.0 - 
Total 142 (100.0%) 275 (100.0%) 417 a   
      
Stratified analysis      
Dark royal blue 91 (64.1%) 91 (33.1%) 182 7.6 (3.6-16.2) <.001 
Pale blue 23 (16.2%) 44 (16.1%) 67 4.0 (1.7-9.3) <.001 
Mixed pattern b 17 (12.0%) 56 (20.4%) 73 2.3 (1.0-5.4) .04 
Not staining 11 (7.8%) 84 (30.6%) 95 1.0 - 
Total 142 (100.0%) 274 (100.0%) 417   
Abbreviations: OSSN, ocular surface squamous neoplasia; OR, odds ratio 477 
a The 2 participants who had equivocal staining results in table 1 are excluded from this table  478 
b Some areas of the lesion were deep royal blue and others pale 479 
Individual percentages may have a rounding error480 
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Table 3. Test performance indices for various levels of toluidine blue vital staining and a comparison of this Kenyan study with 481 
studies from South Africa12 and Brazil11. 482 
Staining result Sensitivity (95%CI) Specificity (95%CI) Positive predictive 
value (95%CI) 
Negative predictive 
value (95%CI) 
Area under the 
ROC curve (95%CI) 
Any blue (dark, pale or mixed) 92% (87% - 96%) 31% (25% - 36%) 41% (35% - 46%) 88% (80% - 94%) .61 (.58 - .65) 
Dark royal blue or pale blue 80% (73% - 87%) 51% (45% - 57%) 46% (40% - 52%) 83% (77% - 89%) .66 (.61 - .70) 
Dark royal blue 64% (56% - 72%) 67% (61% - 72%) 50% (43% - 58%) 78% (72% - 83%) .66 (.61 - .70) 
Pale blue 16% (11% - 23%) 84% (79% - 88%) 34% (23% - 47%) 66% (61% - 71%) .50 (.46 - .54) 
Mixed patterna  12% (7% - 19%) 80% (74% - 84%) 23% (14% - 35%) 64% (58% - 69%) .46 (.42 - .49) 
      
Comparison with other studies       
Parameter Kenya S. Africa Brazilb   
Vital stain dye toluidine blue 0.05% methylene blue 1% toluidine blue 1%   
Number of participants 419 75 47   
Gender, Female No. (%) 277 (66) 45 (60) 18 (38)
Age, median (IQR), y  37 (32-45) 35c 58c   
OSSN prevalence by histopathology No. (%) 142 (34) 33 (44)d 27 (57)   
Sensitivity (95%CI) 92% (87% - 96%) 97% (85% - 100%) 100% (87% - 100%)   
Specificity (95%CI) 31% (25% - 36%) 50% (36% - 65%) 50% (27% - 73%)   
Positive predictive value (95%CI) 41% (35% - 46%) 60% (47% - 72%) 73% (56% - 86%)   
Negative predictive value (95%CI) 88% (80% - 94%) 95% (78% - 99%) 100% (69% - 100%)   
Abbreviations: ROC, receiver operator characteristic; IQR, interquartile range 483 
a Some areas of the lesion were deep royal blue and others pale  484 
b intervals were calculated from the data presented in the paper 485 
c The interquartile range was not reported in S. Africa and Brazil. 486 
d In the South African study, 49 (65%) were on the OSSN spectrum, however, in the analysis that was presented CIN was combined in with benign lesions for the calculation of the test parameters. 487 
 488 
 489 
 490 
 491 
 492 
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Table 4. Inter-observer agreement for the evaluation of ToB staining in 100 patients 493 
Feature Reference Standard
No. (%) 
Six Graders 
Median % 
Agreement 
Median % 
Average Kappa
k (95%CI)c 
Staining resulta   
  Positive 79 (79.0) 76.5% 91.3% 0.76 (0.68 - 0.82)
  Negative 21 (21.0) 23.5%  
Diagnosisb   
  OSSN 32 (32.0) 53.0% 70.7% 0.40 (0.31 - 0.48)
  Non-OSSN 68 (68.0) 47.0%  
a The reference standard for staining was the lead author 494 
b The reference standard for diagnosis was the histopathology result 495 
c The average kappa statistic was obtained by transforming the kappa statistics for each grader to Z scores using the Fisher Z 496 
transformation, averaging and performing a back-transformation.   497 

